USANA Health Sciences, Inc. — Form 10-Q Summary
Period clarification: The request identifies 2017 Q1, but the filing is for the quarter ended March 31, 2018, compared with the quarter ended April 1, 2017. Financial amounts below are in U.S. dollars; figures from the statements are converted from thousands to millions unless otherwise noted.
Business context and reporting period
USANA develops and manufactures nutritional, food, and personal-care/skincare products sold internationally through independent Associates and a direct-selling network. It reported approximately 585,000 active Customers at March 31, 2018. Asia Pacific generated 79.5% of quarterly sales; Greater China alone generated $157.8 million, including $140.6 million in China.
Financial results and liquidity
| Metric | Q1 2018 | Q1 2017 |
|---|---|---|
| Net sales | $292.0 million | $255.3 million |
| Gross profit / gross margin | $242.6 million / 83.1% | $212.7 million / 83.3% |
| Operating earnings / operating margin | $43.1 million / 14.8% | $32.9 million / 12.9% |
| Net earnings / net margin | $28.9 million / 9.9% | $21.4 million / 8.4% |
| Diluted EPS | $1.19 | $0.86 |
| Operating cash flow | $19.5 million | $1.9 million |
Sales increased 14.4% year over year; on a constant-currency basis, sales increased 7.9%. Management attributed the reported increase partly to approximately $11 million from a targeted Mainland China promotion, approximately $9 million from Celavive, and $16.4 million from favorable exchange rates. The effective tax rate was 34.2%, compared with 36.0%.
Cash and cash equivalents were $266.2 million at quarter-end, up from $247.1 million at year-end 2017. Working capital was $239.8 million, versus $199.0 million. The company had no debt outstanding on its $75 million credit line; existing guarantees reduced available borrowing capacity by $5.0 million. Cash, cash equivalents, and restricted cash totaled $269.7 million. Capital expenditures were $2.9 million, and the company repurchased $2.9 million of shares.
Material changes versus the prior comparable quarter
- Greater China sales rose 19.8% reported and 11.3% excluding currency effects; Asia Pacific sales increased 19.0%. Americas and Europe sales declined 0.6% reported and 3.6% excluding currency effects.
- Gross margin declined 0.2 percentage points, which management attributed to sales mix, lower production efficiencies, and higher material costs, partly offset by currency, sales leverage, freight costs, and price adjustments.
- Associate incentives fell to 44.3% of sales from 45.3%, while SG&A increased $6.1 million, reflecting wage and benefit costs, technology investment, and Celavive launch costs.
- Active Customers increased 2.4% to 585,000. Active Associates rose 1.4%; active Preferred Customers rose 2.4%. Americas and Europe Preferred Customers declined 13.4%.
- Operating cash flow improved from $1.9 million to $19.5 million, in part because cash outflows from other liabilities were lower than in the prior-year quarter.
Outlook, commentary, risks, and unusual items
- No numerical earnings or sales guidance is provided. Management’s stated priorities include growing active Customers, launching Celavive in China in Q4 2018, rolling out a WeChat platform in China in Q2, and opening Germany, Spain, Italy, and Romania in mid-June. It targeted a skincare/personal-care run rate of 10% of net sales by year-end 2018.
- Management believes cash, operating cash flow, and available credit will cover ordinary operating and capital needs for the foreseeable future, but notes that adverse conditions or unusual capital requirements could require financing. China profit remittances may be delayed by regulatory requirements; repatriating $7.5 million of indefinitely reinvested earnings would result in an estimated $0.8 million tax liability.
- The company’s voluntary investigation into BabyCare’s China operations remains ongoing. USANA cannot predict its duration, scope, or outcome and may incur further costs or face government proceedings. A related shareholder class action is pending; the court’s decision on the company’s motion to dismiss was pending after argument on April 25, 2018.
- A supplier note previously impaired by $2.7 million was settled in full after quarter-end when the company received $4.8 million in cash. No additional impairment was recorded in Q1.
- USANA adopted ASC 606 in fiscal 2018; the adoption had no material financial-statement impact, though it changed revenue timing for shipped orders not yet delivered. Management reported effective disclosure controls. The filing also identifies foreign-exchange exposure, China operations, network-marketing dependence, regulation, suppliers, and customer/Associate retention among key risks.
Important facts for investors to verify
- Whether reported sales growth and China performance persist after the promotion and currency effects.
- Whether active-Customer trends in the Americas and Europe stabilize, and whether Celavive and planned market launches meet management’s objectives.
- Developments and potential financial consequences of the BabyCare investigation and related shareholder litigation.
- Cash-flow sustainability, cash held outside the United States, credit-line covenant compliance, and the timing or tax effects of any repatriation.
- Whether margin trends improve given production efficiency, material-cost, sales-mix, and foreign-exchange pressures.